Stoke Therapeutics, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 22, 2026. at the 2026-06-03 meeting.
“Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 22, 2026: Shares For Shares Against Shares Withheld/Abstaining Broker Non-Votes 36,436,275 13,565,293 29,415 5,143,930”
Shareholder Votes
Stoke Therapeutics, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-03 meeting.
“Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: Shares For Shares Against Shares Withheld/Abstaining 55,121,163 2,036 51,714”
Shareholder Votes
Stoke Therapeutics, Inc. shareholders approved Election of three Class I directors, G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D. and Julie Anne Smith, each to serve a three-year term. at the 2026-06-03 meeting.
“Election of three Class I directors, G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D. and Julie Anne Smith, each to serve a three-year term, which will expire upon the earlier of the 2029 annual meeting of stockholders or until such time as their respective successors have been duly elected and qualified or their earlier resignation or removal: Nominees Shares For Shares Withheld Broker Non-Votes G. Clare Kahn, Ph.D. 49,722,339 308,644 5,143,930 Adrian Krainer, Ph.D. 36,531,612 13,499,371 5,143,930 Julie Anne Smith 43,500,649 6,530,334 5,143,930”
Earnings Releases
Stoke Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.
“the Company today reported financial results for the first quarter ended March 31, 2026”
Auditor Changes
Stoke Therapeutics, Inc. engaged Ernst & Young LLP as its auditor.
“On March 23, 2026, the Audit Committee approved the engagement of Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Auditor Changes
Stoke Therapeutics, Inc. dismissed KPMG LLP as its auditor.
“On March 23, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Stoke Therapeutics, Inc. (the “Company”) dismissed KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm.”
Material Agreements
Stoke Therapeutics, Inc. entered into Lease Agreement with NWALP PHOP Property Owner LLC valued at approximately 98,500 square feet (effective 2026-01-21).
“On January 21, 2026, Stoke Therapeutics, Inc. (the “Company”) entered into a new lease for its corporate headquarters and laboratory with NWALP PHOP Property Owner LLC, located at 245 Fifth Avenue, Waltham, Massachusetts (the “Lease Agreement”), in order to expand its office and laboratory space.”
Arthur Tzianabos was appointed as Interim Executive Chair at Stoke Therapeutics, Inc..
“Also in connection with Dr. Kaye’s transition, effective as of the Transition Date, the Board appointed Arthur Tzianabos, 61, currently Chair of the Board, as Interim Executive Chair of the Board.”
Ian F. Smith was appointed as Interim Chief Executive Officer at Stoke Therapeutics, Inc..
“Effective as of the Transition Date, the Board appointed Ian F. Smith, 59, a director on the Board, to succeed Dr. Kaye as Interim Chief Executive Officer (“Interim CEO”).”
Edward Kaye departed as Chief Executive Officer at Stoke Therapeutics, Inc..
“On March 16, 2025, Dr. Edward Kaye, M.D., 75, the Company’s Chief Executive Officer (“CEO”) and a director, informed the Company’s Board of Directors (the “Board”) of his intention to step down from his position as the Company’s CEO, effective March 19, 2025 (the “Transition Date”).”
Huw Nash changed role as Chief Operating Officer at Stoke Therapeutics, Inc..
“On June 18, 2024, Stoke Therapeutics, Inc. (the “Company”) and Huw Nash, Ph.D., the Company’s Chief Operating Officer and Chief Business Officer, announced that they have mutually agreed that Dr. Nash would step down from his position as Chief Operating Officer, effective immediately.”
Earnings Releases
Stoke Therapeutics, Inc. reported the three months ended March 31, 2024 results: revenue $4.2 million, net income $26.4 million, EPS $0.57 per share.
“Revenue recognized for upfront license fees and services provided from a License and Collaboration Agreement with Acadia Pharmaceuticals for the three months ended March 31, 2024 was $4.2 million, compared to $5.2 million, for the same period in 2023.”
Stephen Tulipano resigned as Chief Financial Officer at Stoke Therapeutics, Inc..
“Resignation of Chief Financial Officer Effective as of the Appointment Date, the Company’s current Chief Financial Off”
Thomas Leggett was appointed as Chief Financial Officer at Stoke Therapeutics, Inc..
“appointed Thomas Leggett as the Chief Financial Officer of the Company”
Material Agreements
Stoke Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC valued at approximately $119.8 million (effective 2024-03-27).
“On March 27, 2024, Stoke Therapeutics, Inc., a Delaware corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC as representative of the underwriters named therein (the “Underwriter”), pursuant to which the Company agreed to issue and sell 5,555,557 shares (the “Underwritten Shares”) of its common stock, par value $0.0001 per share (“Common Stock”) to the Underwriter in a public offering at a price of $13.50 per Underwritten Share”
Earnings Releases
Stoke Therapeutics, Inc. reported the full year ended December 31, 2023 results: revenue $8.8 million, net income $104.7 million, or $2.38 per share, EPS $2.38 per share.
“Revenue recognized for upfront license fees and services provided from a License and Collaboration Agreement with Acadia Pharmaceuticals for the year ended December 31, 2023 was $8.8 million, compared to $12.4 million, for the year ended December 31, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.